Author(s):
Gunuputi Sushma, Sri Harsha D, Mathrusri Annapurna Mukthinuthalapati
Email(s):
mmukthin@gitam.edu
DOI:
10.5958/0974-360X.2020.00505.3 
Address:
Gunuputi Sushma, Sri Harsha D, Mathrusri Annapurna Mukthinuthalapati*
Department of Pharmaceutical Analysis, Gandhi Institute of Technology and Management, GITAM Institute of Pharmacy, Visakhapatnam, Andhra Pradesh-530045, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 6,
Year - 2020
ABSTRACT:
New first derivative spectrophotometric methods have been established for the determination of Sitagliptin in pharmaceutical formulations. Sitagliptin is an oral dipeptidyl peptidase-4 inhibitor which exerts its actions in type 2 diabetes patients by slowing the inactivation of incretin hormones. Sitagliptin is chemically known as (R)-4-oxo-4- [3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo [4,3-a] pyrazin -7(8H) -yl] -1-(2,4,5-trifluoro phenyl)butan-2-amine. First derivative spectrophotometric methods were developed using the reagents 0.1 N NaOH, phosphate buffers (pH 5.0 and 8.0), borate buffer (pH 9.0) and acetate buffer (pH 4.7) and amplitude was taken as the parameter from the derivative spectra to construct the calibration curve. Sitagliptin obeys Beer-Lambert’s law over the concentration range 5-100 µg/ml in all the methods and the methods were validated as per ICH guidelines.
Cite this article:
Gunuputi Sushma, Sri Harsha D, Mathrusri Annapurna Mukthinuthalapati. New first derivative spectrophotometric methods for the determination of Sitagliptin - An antidiabetic agent. Research J. Pharm. and Tech 2020; 13(6): 2838-2842. doi: 10.5958/0974-360X.2020.00505.3
Cite(Electronic):
Gunuputi Sushma, Sri Harsha D, Mathrusri Annapurna Mukthinuthalapati. New first derivative spectrophotometric methods for the determination of Sitagliptin - An antidiabetic agent. Research J. Pharm. and Tech 2020; 13(6): 2838-2842. doi: 10.5958/0974-360X.2020.00505.3 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-55
REFERENCES:
1. Ahren B. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia. 2005; 48: 605–607.
2. Ravisankar P, Mounika G, Devadasu Ch and Devala Rao G. A simple validated UV spectrophotometric method for quantitative analysis of Sitagliptin phosphate in pharmaceutical dosage form. Journal of Chemical and Pharmaceutical Sciences. 2014; 7(3): 254-258.
3. Jain Pritam, Chaudhari Amar, Desai Bhargav, Patel Shani, Patel Santsaran and Shimpi Hiren. Development and validation of first order derivative UV-Spectrophotometric method for determination of Sitagliptin in bulk and in formulation. International Journal of Drug Development and Research. 2011; 3(4): 194-199.
4. Maste Meenaxi M, Bhat AR, Mohite Mukesh and Patil Deepak. spectrophotometric method for estimation of Sitagliptin phosphate in bulk and tablet dosage form. International Journal of Pharmaceutical Formulation and Analysis. 2011; 2(2): 47-50.
5. Vinit Chavhan and Atul Kadam. UV Spectrophotometric method development and validation for estimation of Sitagliptin phosphate in bulk and tablet dosage form by absorption ratio and area under the curve method. Journal of Biological and Scientific Opinion. 2013; 1(4): 317-322.
6. Parag Pathade, Md Imran, Vinod Bairag and Yogesh Ahire. Development and validation of stability indicating UV spectrophotometric method for the estimation of Sitagliptin phosphate in bulk and tablet dosage form. Journal of Pharmacy Research. 2011; 4(3): 871-873.
7. Sushma G, Sri Harsha D and Mathrusri Annapurna M. Development and validation of new spectrophototmetric methods for the determination of Sitagliptin. Acta Scientific Pharmaceutical Sciences. 2020; 4(3): 1-5.
8. Jeyabalan G and Narendra Nyola. Analytical method development and validation of Sitagliptine phosphate monohydrate in pure and tablet dosage form by derivative spectroscopy. Journal of Applied Pharmaceutical Science. 2013; 3(1): 95-98.
9. Jalkote RN and Kalshetti MS. UV Spectrophotometric method development and validation for determination of Sitagliptin in api and in pharmaceutical dosage form. World Journal of Pharmacy and Pharmaceutical Sciences. 2019; 8(5): 916-925.
10. Patil Sachin, Ramesh B, Hareesh AR and Patil Kiran. Validated UV spectrophotometric method for estimation of Sitagliptin phosphate in tablet dosage form. Research Journal of Pharmacy and Technology. 2010; 3(3): 798-800.
11. Saad Antakli, Nazeera Sarkees and Mais Hazzouri. Spectrophotometric determination of Sitagliptin in tablets formulations. Asian Journal of Chemistry. 2015; 27(1): 375-378.
12. Bala Sekaran C and Prameela Rani A. Development and validation of spectrophotometric method for the determination of DPP-4 inhibitor Sitagliptin in its pharmaceutical preparations. Eclética Química. 2010; 35(3): 45-53.
13. Deepanjali Mohanty, Patro SK, Prusty AK and Sahu SK. Extractive spectrophotometric estimation of Sitagliptin phosphate. International Journal of ChemTech Research. 2017; 10(4): 255-263.
14. Disha NS and Gurupadhayya BM. Spectrophotometric determination of Sitagliptin phosphate in bulk and pharmaceutical formulations. International Journal of Innovative Science, Engineering and Technology. 2015; 2(7): 702-709.
15. Tarkase KN, Madhuri B, Sumit AG and Ashwini Gawade. Development and validation of UV spectrophotometric method for estimation of Sitagliptin phosphate. Der Pharmacia Lettre. 2013; 5(3): 315-318.
16. Namratha Sunkara, Kandala Neela Maneesha, Lavanya B and Sanapala Arunkumar. UV spectrophotometric method development and validation of sitagliptin in bulk and pharmaceutical dosage form. International Journal of Pharma and Chemical Research. 2017; 3(3): 577-580.
17. J.Anudeepa, R.Manavalan and R.Venkatanarayanan: Development of UV‐spectrophotometric method for Sitagliptin in bulk and pharmaceutical formulation. International Journal of Science, Engineering and Technology. 2015; 3(5): 1352-1354.
18. ICH Q2 [R1] validation of analytical procedures: Text and Methodology: November (2005).